Pacira BioSciences Inc PCRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PCRX is a good fit for your portfolio.
News
-
Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications
-
Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in November
-
Pacira BioSciences Reports Third Quarter 2023 Financial Results
-
Pacira to Report Third Quarter 2023 Financial Results on Thursday November 2, 2023
-
American Society of Anesthesiologists Announces New Industry Supporter Pacira BioSciences, Inc.
-
Pacira BioSciences Appoints Four New Independent Directors to its Board of Directors
-
American Society of Anesthesiologists and Pacira BioSciences, Inc. Announce New Grant to Advance Education and Enhance Patient Care
-
Pacira BioSciences Announces Leadership Succession Plan
Trading Information
- Previous Close Price
- $28.47
- Day Range
- $28.08–28.74
- 52-Week Range
- $25.94–48.58
- Bid/Ask
- $28.53 / $28.60
- Market Cap
- $1.33 Bil
- Volume/Avg
- 48,952 / 498,951
Key Statistics
- Price/Earnings (Normalized)
- 10.07
- Price/Sales
- 1.97
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has launched EXPAREL which utilizes DepoFoam, a product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 715
- Website
- https://www.pacira.com
Valuation
|
Metric
|
PCRX
|
|---|---|
Price/Earnings (Normalized) | 10.07 |
Price/Book Value | 1.59 |
Price/Sales | 1.97 |
Price/Cash Flow | 7.24 |
Price/Earnings
PCRX
Financial Strength
|
Metric
|
PCRX
|
|---|---|
Quick Ratio | 3.55 |
Current Ratio | 4.78 |
Interest Coverage | 0.96 |
Quick Ratio
PCRX
Profitability
|
Metric
|
PCRX
|
|---|---|
Return on Assets (Normalized) | 8.35% |
Return on Equity (Normalized) | 16.94% |
Return on Invested Capital (Normalized) | 9.72% |
Return on Assets
PCRX
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Spq | $83.6 Bil | |
MKKGY
| Merck KGaA ADR | Rhdsnwq | $77.2 Bil | |
HLN
| Haleon PLC ADR | Gpcz | $38.6 Bil | |
VTRS
| Viatris Inc | Gxqk | $11.6 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Nvdg | $11.5 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Xkx | $11.1 Bil | |
CTLT
| Catalent Inc | Ddjgtk | $7.2 Bil | |
PRGO
| Perrigo Co PLC | Bnmps | $4.2 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Sqgmg | $3.0 Bil | |
CURLF
| Curaleaf Holdings Inc | Cqswy | $2.8 Bil |